Blood supply
This article was originally published in The Gray Sheet
Executive Summary
FDA and the American Red Cross fail to identify a mutually acceptable system of prospective fines for future blood bank safety violations after sixteen months of negotiations related to quality assurance oversight of blood donations. According to FDA, the Red Cross has not abided by a 1993 consent decree in which it promised to make significant improvements in blood safety oversight at its national headquarters and regional facilities. On Dec. 11, the agency asked a federal court for authority to impose prospective fines against the Red Cross for future violations in order to force conformance to the consent decree...
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.